Physician profile
Michael S Corcoran
NPI 1346210853
$6,206.83
in general payments reported to CMS, 2019-2025
56 companies · $1,442 in 2025
The $1,442 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,068 · 2022: $916 · 2023: $1,376 · 2024: $1,405 · 2025: $1,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,222.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,524.66 | 2021-2025 | |
| Pfizer INC. | $651.76 | 2022-2025 | |
| Amgen INC. | $322.87 | 2021-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $299.82 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $238.44 | 2021-2024 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.41 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.94 | 2021-2024 | |
| Lilly USA, LLC | $164.60 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Novartis Pharmaceuticals Corporation | $147.54 | 2021-2024 | |
| Astellas Pharma US INC | $144.30 | 2021-2025 | Veozah |
| Glaxosmithkline, LLC. | $140.02 | 2021-2025 | Shingrix, Arexvy |
| Alexion Pharmaceuticals, INC. | $128.67 | 2023-2025 | Strensiq |
| Boston Scientific Corporation | $112.46 | 2022-2025 | General - Therapies, Watchman Access System, Wavewriter Alpha Prime 16 |
| Paratek Pharmaceuticals, INC. | $109.64 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $107.40 | 2024-2025 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $94.41 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $93.51 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Esperion Therapeutics, INC. | $91.58 | 2021-2024 | Nexletol |
| Sumitomo Pharma America, INC. | $83.52 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $80.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $74.39 | 2022-2024 | Sunosi |
| Otsuka America Pharmaceutical, INC. | $74.04 | 2023-2024 | Nuedexta, Rexulti |
| Idorsia Pharmaceuticals US INC | $64.28 | 2023-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $58.11 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $56.43 | 2022 | |
| Inogen, INC. | $55.13 | 2023-2025 | Inogen |
| Harmony Biosciences LLC | $53.42 | 2023-2024 | Wakix |
| Radius Health, INC. | $53.09 | 2023 | Tymlos |
| Edwards Lifesciences Corporation | $48.88 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Abbott Laboratories | $42.59 | 2024 | Freestyle Libre 3 |
| Lucid Diagnostics INC. | $42.05 | 2022 | |
| Nestle Healthcare Nutrition INC. | $41.91 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $41.05 | 2021-2023 | Eliquis |
| Nevro Corp. | $40.32 | 2022-2023 | Senza |
| Biohaven Pharmaceuticals, INC. | $40.02 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $38.37 | 2021-2023 | Airduo Digihaler |
| Janssen Pharmaceuticals, INC | $37.83 | 2023-2024 | Xarelto, Spravato |
| Ibsa Pharma INC. | $35.44 | 2021-2025 | Licart, Flector, Tirosint |
| Takeda Pharmaceuticals U.S.A., INC. | $35.41 | 2024-2025 | Trintellix |
| Horizon Therapeutics Plc | $34.35 | 2022-2023 | Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.55 | 2025 | |
| Sunovion Pharmaceuticals INC. | $33.02 | 2021 | |
| Aimmune Therapeutics, INC. | $32.17 | 2024-2025 | Zenpep |
| Seqirus USA INC | $27.74 | 2021-2022 | |
| Lundbeck LLC | $24.49 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $24.43 | 2025 | |
| Phadia US INC. | $23.68 | 2025 | Immunocap |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.11 | 2022 | |
| Ossur Americas, INC. | $22.29 | 2025 | |
| Abiomed | $19.02 | 2025 | |
| Jazz Pharmaceuticals INC. | $18.66 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.53 | 2021 | |
| Alkermes, INC. | $15.76 | 2022 | |
| Acella Pharmaceuticals, LLC | $15.19 | 2025 | NP Thyroid 60 |
| Biotronik INC. | $14.84 | 2022 | |
| Adlon Therapeutics L.P. | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Corcoran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.